Article
Oncology
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, Ramon Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar-Company, Mark Bower, Rachel Sharkey, Alessia Dalla Pria, Andrea Plaja, Amanda Jackson, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martinez-Vila, Marta Matas, Ana Miguel Rodriguez, Bruno Vincenzi, Giuseppe Tonini, Alexia Bertuzzi, Joan Brunet, Paolo Pedrazzoli, Francesca D'Avanzo, Federica Biello, Alasdair Sinclair, Alvin J. X. Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, Maria Iglesias, Ana Sanchez de Torre, Annalisa Guida, Rossana Berardi, Alberto Zambelli, Carlo Tondini, Marco Filetti, Francesca Mazzoni, Uma Mukherjee, Nikolaos Diamantis, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Michela Libertini, Salvatore Grisanti, Maura Rossi, Federica Zoratto, Daniele Generali, Cristina Saura, Gary H. Lyman, Nicole M. Kuderer, David J. Pinato, Alessio Cortellini
Summary: Although breast cancer patients have lower mortality rates from COVID-19, it is important to evaluate the impact of the pandemic in different phases and the effectiveness of vaccination to inform clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Flavia Jacobs, Mariangela Gaudio, Chiara Benvenuti, Rita De Sanctis, Armando Santoro, Alberto Zambelli
Summary: Great progress has been made in personalized treatment for breast cancer oncology, with the introduction of genomic signature testing being particularly important. The aim of this review is to discuss the challenges and urgent issues related to its daily use, providing insights for better integration and wider application in clinical practice. The review focuses on the integration of genomic data with clinicopathological factors, the potential clinical impact of genomic testing in different patient populations and settings, and the optimization of test ordering.
Article
Oncology
Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano
Summary: Patients with germinal BRCA pathogenic variant and advanced breast cancer may have enhanced sensitivity to platinum-based chemotherapy and PARP inhibitors. However, the sensitivity and resistance to these treatments may partially overlap. The impact of prior exposure to PARP inhibitors/platinum-based chemotherapy on tumor response to subsequent treatment remains unclear.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia Bianchi, Lucia Del Mastro, Ida Paris, Filippo Montemurro, Giacomo Allegrini, Marco Colleoni, Stefano Tamberi, Claudio Zamagni, Marina E. Cazzaniga, Michele Orditura, Valentina Guarneri, Daniela Castelletti, Matteo Benelli, Mariacristina Di Marino, Grazia Arpino, Michelino De Laurentiis
Summary: In this study, it was found that serum TK1 activity (sTKa) can serve as a novel prognostic and pharmacodynamic biomarker in patients with HR+/HER2- ABC treated with ribociclib plus letrozole as first-line therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Surgery
Fabio Corsi, Sara Albasini, Simone Ciciriello, Laura Villani, Marta Truffi, Marta Sevieri, Luca Sorrentino
Summary: This study aimed to assess the impact of extensive intraductal component (EIC) on 5-year survival outcomes in patients with early breast cancer treated with breast-conserving surgery. The results showed that the absence of EIC was associated with worse 5-year disease-free survival (DFS) and distant metastasis-free survival (DMFS). EIC increased 5-year DFS in T1 patients but not in T2 stage, and it was associated with better DFS in G2 and G3 patients but not in G1 cases.
JOURNAL OF SURGICAL RESEARCH
(2023)
Letter
Biochemistry & Molecular Biology
Harrison G. Zhang, Jacqueline P. Honerlaw, Monika Maripuri, Malarkodi Jebathilagam Samayamuthu, Brendin R. Beaulieu-Jones, Huma S. Baig, Sehi L'Yi, Yuk-Lam Ho, Michele Morris, Vidul Ayakulangara Panickan, Xuan Wang, Griffin M. Weber, Katherine P. Liao, Shyam Visweswaran, Bryce W. Q. Tan, William Yuan, Nils Gehlenborg, Sumitra Muralidhar, Rachel B. Ramoni, Isaac S. Kohane, Zongqi Xia, Kelly Cho, Tianxi Cai, Gabriel A. Brat, James R. Aaron, Giuseppe Agapito, Adem Albayrak, Giuseppe Albi, Mario Alessiani, Anna Alloni, Danilo F. Amendola, Francois Angoulvant, Li L. L. J. Anthony, Bruce J. Aronow, Fatima Ashraf, Andrew Atz, Paul Avillach, Paula S. Azevedo, James Balshi, Brett K. Beaulieu-Jones, Douglas S. Bell, Antonio Bellasi, Riccardo Bellazzi, Vincent Benoit, Michele Beraghi, Jose Luis Bernal-Sobrino, Melodie Bernaux, Romain Bey, Surbhi Bhatnagar, Alvar Blanco-Martinez, Clara-Lea Bonzel, John Booth, Silvano Bosari, Florence T. Bourgeois, Robert L. Bradford, Gabriel A. Brat, Stephane Breant, Nicholas W. Brown, Raffaele Bruno, William A. Bryant, Mauro Bucalo, Emily Bucholz, Anita Burgun, Tianxi Cai, Mario Cannataro, Aldo Carmona, Charlotte Caucheteux, Julien Champ, Jin Chen, Krista Y. Chen, Luca Chiovato, Lorenzo Chiudinelli, Kelly Cho, James J. Cimino, Tiago K. Colicchio, Sylvie Cormont, Sebastien Cossin, Jean B. Craig, Juan Luis Cruz-Bermudez, Jaime Cruz-Rojo, Arianna Dagliati, Mohamad Daniar, Christel Daniel, Priyam Das, Batsal Devkota, Audrey Dionne, Rui Duan, Julien Dubiel, Scott L. DuVall, Loic Esteve, Hossein Estiri, Shirley Fan, Robert W. Follett, Thomas Ganslandt, Noelia Garcia-Barrio, Lana X. Garmire, Nils Gehlenborg, Emily J. Getzen, Alon Geva, Tobias Gradinger, Alexandre Gramfort, Romain Griffier, Nicolas Griffon, Olivier Grisel, Alba Gutierrez-Sacristan, Larry Han, David A. Hanauer, Christian Haverkamp, Derek Y. Hazard, Bing He, Darren W. Henderson, Martin Hilka, Yuk-Lam Ho, John H. Holmes, Chuan Hong, Kenneth M. Huling, Meghan R. Hutch, Richard W. Issitt, Anne Sophie Jannot, Vianney Jouhet, Ramakanth Kavuluru, Mark S. Keller, Chris J. Kennedy, Daniel A. Key, Katie Kirchoff, Jeffrey G. Klann, Isaac S. Kohane, Ian D. Krantz, Detlef Kraska, Ashok K. Krishnamurthy, Sehi L'Yi, Trang T. Le, Judith Leblanc, Guillaume Lemaitre, Leslie Lenert, Damien Leprovost, Molei Liu, Ne Hooi Will Loh, Qi Long, Sara Lozano-Zahonero, Yuan Luo, Kristine E. Lynch, Sadiqa Mahmood, Sarah E. Maidlow, Adeline Makoudjou, Alberto Malovini, Kenneth D. Mandl, Chengsheng Mao, Anupama Maram, Patricia Martel, Marcelo R. Martins, Jayson S. Marwaha, Aaron J. Masino, Maria Mazzitelli, Arthur Mensch, Marianna Milano, Marcos F. Minicucci, Bertrand Moal, Taha Mohseni Ahooyi, Jason H. Moore, Cinta Moraleda, Jeffrey S. Morris, Michele Morris, Karyn L. Moshal, Sajad Mousavi, Danielle L. Mowery, Douglas A. Murad, Shawn N. Murphy, Thomas P. Naughton, Carlos Tadeu Breda Neto, Antoine Neuraz, Jane Newburger, Kee Yuan Ngiam, Wanjiku F. M. Njoroge, James B. Norman, Jihad Obeid, Marina P. Okoshi, Karen L. Olson, Gilbert S. Omenn, Nina Orlova, Brian D. Ostasiewski, Nathan P. Palmer, Nicolas Paris, Lav P. Patel, Miguel Pedrera-Jimenez, Emily R. Pfaff, Ashley C. Pfaff, Danielle Pillion, Sara Pizzimenti, Hans U. Prokosch, Robson A. Prudente, Andrea Prunotto, Victor Quiros-Gonzalez, Rachel B. Ramoni, Maryna Raskin, Siegbert Rieg, Gustavo Roig-Dominguez, Pablo Rojo, Paula Rubio-Mayo, Paolo Sacchi, Carlos Saez, Elisa Salamanca, Malarkodi Jebathilagam Samayamuthu, L. Nelson Sanchez-Pinto, Arnaud Sandrin, Nandhini Santhanam, Janaina C. C. Santos, Fernando J. Sanz Vidorreta, Maria Savino, Emily R. Schriver, Petra Schubert, Juergen Schuettler, Luigia Scudeller, Neil J. Sebire, Pablo Serrano-Balazote, Patricia Serre, Arnaud Serret-Larmande, Mohsin Shah, Zahra Shakeri Hossein Abad, Domenick Silvio, Piotr Sliz, Jiyeon Son, Charles Sonday, Andrew M. South, Anastasia Spiridou, Zachary H. Strasser, Amelia L. M. Tan, Bryce W. Q. Tan, Byorn W. L. Tan, Suzana E. Tanni, Deanne M. Taylor, Ana I. Terriza-Torres, Valentina Tibollo, Patric Tippmann, Emma M. S. Toh, Carlo Torti, Enrico M. Trecarichi, Yi-Ju Tseng, Andrew K. Vallejos, Gael Varoquaux, Margaret E. Vella, Guillaume Verdy, Jill-Jenn Vie, Shyam Visweswaran, Michele Vitacca, Kavishwar B. Wagholikar, Lemuel R. Waitman, Xuan Wang, Demian Wassermann, Griffin M. Weber, Martin Wolkewitz, Scott Wong, Zongqi Xia, Xin Xiong, Ye Ye, Nadir Yehya, William Yuan, Alberto Zambelli, Harrison G. Zhang, Daniela Zoller, Valentina Zuccaro, Chiara Zucco
Review
Genetics & Heredity
Mattia Garutti, Lorenzo Foffano, Roberta Mazzeo, Anna Michelotti, Lucia Da Ros, Alessandra Viel, Gianmaria Miolo, Alberto Zambelli, Fabio Puglisi
Summary: Hereditary cancer syndromes, though often underdiagnosed, account for nearly 10% of cancers. Identifying pathogenic gene variants could have significant implications for treatment, prevention, and testing, but diagnosing these syndromes can be challenging due to lack of validated criteria and suboptimal performance. Many clinicians are not adequately trained to select patients for genetic testing. This review categorizes hereditary cancer syndromes affecting adults and provides a visual tool to help clinicians in their daily practice.
Review
Oncology
Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Chemotherapy has been the mainstay, but recent studies have shown immune checkpoint inhibitors to be effective as first-line treatment for advanced TNBC expressing PD-L1. However, there are still many open questions regarding the use of immunotherapy in TNBC.
Review
Oncology
Chiara Benvenuti, Paola Tiberio, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Sebastiano Pindilli, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: In breast cancer management, neoadjuvant chemotherapy is widely used, but there is a lack of technology that can predict the benefits of neoadjuvant chemotherapy for breast cancer patients. Circulating miRNAs have emerged as potential non-invasive biomarkers for breast cancer and may be useful in diagnosing, predicting, and prognosticating breast cancer patients undergoing neoadjuvant chemotherapy. Among circulating miRNAs, miR-21-5p and miR-34a-5p are the most promising biomarkers for breast cancer patients undergoing neoadjuvant chemotherapy.
Article
Oncology
Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli, Andrea Vingiani, Edda Lucia Simoncini, Giancarlo Pruneri, Elisabetta Munzone, Giampaolo Bianchini, Alberto Zambelli, Carlo Tondini
Summary: The increasing understanding of breast cancer biology has led to the development of multigene signatures to improve prognostication and risk stratification. The use of these tools in clinical practice has greatly influenced treatment decisions for patients with ER+/HER2- early breast cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.
Article
Oncology
L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici
Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.
Review
Biochemistry & Molecular Biology
Paola Tiberio, Alessandro Vigano, Mariya Boyanova Ilieva, Sebastiano Pindilli, Anna Bianchi, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: Numerous epidemiological studies have explored the potential link between migraine and breast cancer due to their association with female reproductive hormones. Current evidence suggests a protective role of migraine in breast cancer development, particularly in case-control studies. However, the inconsistency among studies and recent research challenging this concept indicate a more complex relationship between the two conditions. Further studies are needed to validate the protective role of migraine in breast cancer and identify the precise nature of this causal relationship.
Review
Biochemistry & Molecular Biology
Chiara Benvenuti, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Rita De Sanctis, Rosalba Torrisi, Armando Santoro, Alberto Zambelli
Summary: Visceral crisis is a life-threatening condition in advanced breast cancer, but its clinical definition is unclear, making it challenging to manage. Chemotherapy is recommended as first-line treatment, but its effectiveness is limited and the prognosis is poor. The available evidence is mainly from retrospective studies, and the role of chemotherapy is questioned with the introduction of innovative drugs. This article aims to critically discuss the management of visceral crisis and explore future treatment perspectives.
Review
Oncology
Paola Tiberio, Mariangela Gaudio, Silvia Belloni, Sebastiano Pindilli, Chiara Benvenuti, Flavia Jacobs, Giuseppe Saltalamacchia, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: In recent decades, neoadjuvant chemotherapy has been proven to reduce tumor size and improve surgical outcomes in high-risk early or locally advanced breast cancer. However, individual responses to therapy and long-term prognosis remain unpredictable. Circulating microRNAs have emerged as potential non-invasive biomarkers for breast cancer management, but discrepancies between studies hinder their implementation in clinical practice.